Detalles de la búsqueda
1.
Improvement in immune dysfunction after FOLFOX chemotherapy for Stage III colon cancer is associated with improved minimal residual disease prognostic subtype and outcome.
Colorectal Dis
; 23(11): 2879-2893, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34473913
2.
The association of the neutrophil-lymphocyte ratio with the presence of minimal residual disease and outcome in patients with Stage II colon cancer treated with surgery alone.
Colorectal Dis
; 23(4): 805-813, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33169474
3.
Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management.
Biol Res
; 51(1): 32, 2018 Sep 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30180883
4.
Prediction model for early biochemical recurrence after radical prostatectomy based on the Cancer of the Prostate Risk Assessment score and the presence of secondary circulating prostate cells.
BJU Int
; 118(4): 556-62, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-26507242
5.
Immune dysfunction, minimal residual disease and patient outcome in nonmetastatic cancer: could modulation of immune function improve outcome?
Future Oncol
; 17(13): 1571-1575, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33626930
6.
Editorial Comment.
J Urol
; 202(4): 740-741, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31766090
7.
Elimination of primary circulating prostate cells after radical prostatectomy for prostate cancer decreases the risk of future biochemical failure.
Arch Esp Urol
; 67(8): 684-91, 2014 Oct.
Artículo
en Inglés, Español
| MEDLINE | ID: mdl-25306986
8.
Biomarkers of minimal residual disease and treatment.
Adv Clin Chem
; 119: 33-70, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38514211
9.
Secondary circulating prostate cells predict biochemical failure in prostate cancer patients after radical prostatectomy and without evidence of disease.
ScientificWorldJournal
; 2013: 762064, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23653529
10.
Cost-Benefit of incorporating the detection of circulating prostate cells in a screening programme for prostate cancer.
Arch Esp Urol
; 66(3): 277-86, 2013 Apr.
Artículo
en Inglés, Español
| MEDLINE | ID: mdl-23648747
11.
The Possible Role of Matrix Metalloprotienase-2 in the Relapse in Patients with Stage II Colon Cancer Treated by Curative Surgery.
Asian Pac J Cancer Prev
; 24(10): 3373-3379, 2023 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37898840
12.
Atypical presentation of COVID-19: Chronic bilateral testicular pain with lower extremity peripheral polyneuropathy, case report.
Urol Case Rep
; 40: 101932, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34778003
13.
Increasing Immune Dysfunction is Associated with Increasing Matrix-Metalloproteinase-2 Expression and Predicts Biochemical Failure in Men with Bone Marrow Micro-Metastasis Positive Localized Prostate Cancer.
Asian Pac J Cancer Prev
; 23(7): 2497-2505, 2022 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35901359
14.
The CAPRA-S Score and Immune Dysfunction as a Guide to Outcome in Men Treated with Prostatectomy Radical as Mono-Therapy for Prostate Cancer.
Arch Esp Urol
; 75(6): 507-516, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-36138499
15.
Improvement in the Neutrophil-Lymphocyte Ratio after Combined Fluorouracil, Leucovorina and Oxaliplatino based (FOLFOX) Chemotherapy for Stage III Colon Cancer is Associated with Improved Minimal Residual Disease and Outcome.
Asian Pac J Cancer Prev
; 23(2): 591-599, 2022 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35225472
16.
Diagnostic performance of malignant prostatic cells detection in blood for early detection of prostate cancer: comparison to prostatic biopsy.
Arch Esp Urol
; 64(10): 961-71, 2011 Dec.
Artículo
en Inglés, Español
| MEDLINE | ID: mdl-22228894
17.
Immune Dysfunction as Measured by the Systemic Immune-Inflammation Index is Associated with the Sub-Type of Minimal Residual Disease and Outcome in Stage II Colon Cancer Treated with Surgery alone.
Asian Pac J Cancer Prev
; 22(8): 2391-2397, 2021 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34452551
18.
[CAPRA score vs minimal residual disease as predictors of biochemical recurrence after radical prostatectomy.] / La puntuación CAPRA frente a los subtipos de enfermedad residual mínima para predecir la recidiva bioquímica después de la prostatectomía radical.
Arch Esp Urol
; 74(6): 554-563, 2021 Jul.
Artículo
en Español
| MEDLINE | ID: mdl-34219057
19.
Detection and characteristics of primary circulating prostate cells; association with micrometastasis and implications for surgical treatment of men with prostate cancer.
Arch Esp Urol
; 63(5): 345-53, 2010 Jun.
Artículo
en Inglés, Español
| MEDLINE | ID: mdl-20587839
20.
Platelet-to-lymphocyte ratio and systemic immune-inflammation index versus circulating prostate cells to predict significant prostate cancer at first biopsy.
Turk J Urol
; 46(2): 115-122, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32053099